Pfizer announces positive results from phase 3 study of 20-valent pneumococcal conjugate vaccine Medical Dialogues Bureau22 March 2020 3:30 AM GMTNew York: Pfizer Inc. has announced top-line results from one of its Phase 3 studies, which evaluated the safety and immunogenicity of its 20-valent...